Your browser doesn't support javascript.
loading
[Translated article] Study of the Impact of Restrictions on Access to Biological Drugs for the Management of Psoriasis on the Minimum Disease Activity Criteria: Subanalysis of AEDV EQUIDAD and AME Projects.
Sánchez-Díaz, M; Flórez, Á; Carretero-Hernández, G; Grau-Pérez, M; García-Doval, I; Carrascosa-Carrillo, J M.
Afiliação
  • Sánchez-Díaz M; Unidad de Investigación, Fundación Piel Sana de la Academia Española de Dermatología y Venereología, Madrid, Spain; Servicio de Dermatología, Hospital Universitario Virgen de las Nieves Instituto de Investigación Biosanitaria IBS, Granada, Spain.
  • Flórez Á; Servicio de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Grupo de Investigación DIPO, IIS Galicia Sur-SERGAS-UVIGO, Pontevedra, Spain.
  • Carretero-Hernández G; Servicio de Dermatología, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Isla de Gran Canaria, Spain.
  • Grau-Pérez M; Servicio de Dermatología, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain; Unidad de Investigación, Fundación Piel Sana de la Academia Española de Dermatología y Venereología, Madrid, Spain.
  • García-Doval I; Unidad de Investigación, Fundación Piel Sana de la Academia Española de Dermatología y Venereología, Madrid, Spain; Servicio de Dermatología, Hospital do Meixoeiro, Vigo, Pontevedra, Spain. Electronic address: ignacio.garcia.doval@sergas.es.
  • Carrascosa-Carrillo JM; Servicio de Dermatología, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain.
Actas Dermosifiliogr ; 2024 Aug 03.
Article em En, Es | MEDLINE | ID: mdl-39102977
ABSTRACT
Spanish Autonomous Communities (ACs) are entitled to decide on the prescription requirements of their own territories, which can create inequalities in access to new drugs in the management of psoriasis. The objective of this study was to assess whether the level of restrictions in the access to new drugs for the management psoriasis was associated with the probability of achieving disease control measured using the Minimum Disease Activity (MDA) criteria. Therefore, we combined the results of 2 previous independent, cross-sectional studies one that described the MDA in psoriasis by AC, and another that evaluated the level of restrictions to drug access by AC. We found that the higher the number of restrictions the lower the chances of achieving the MDA criteria (P=.013). Our results suggest that, in Spain, geographical differences in the access to new drugs may be creating health inequalities across the country.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En / Es Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En / Es Ano de publicação: 2024 Tipo de documento: Article